Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.38 |
| ▸ | KCNB1 | Q14721 | 3/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.38 |
| ▸ | Q9HBH1 | 1/20 | 0.37 | |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19445715 | 1.00 | KLKB1 (0.41) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL12515368 | 0.99 | KLKB1 (0.41) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL19445643 | 0.91 | ALDH1A1 (0.43) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL10261754 | 0.91 | ERAP2 (0.46) | KLKB1TSHRMMP2HDAC1ERAP2 | |
| SCHEMBL21371927 | 0.91 | KLKB1 (0.41) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL19944772 | 0.91 | KLKB1 (0.41) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL12766955 | 0.90 | MMP2 (0.43) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL10262850 | 0.90 | KLKB1 (0.42) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL12515365 | 0.90 | ALDH1A1 (0.43) | KLKB1TSHRMMP2HDAC1KMT2A | |
| SCHEMBL12767238 | 0.90 | ALDH1A1 (0.43) | KLKB1TSHRMMP2HDAC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | KLKB1 1324/4885TSHR 4275/4885MMP2 367/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | KLKB1 1324/4885TSHR 4275/4885MMP2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.